Journal
ONCOLOGIST
Volume -, Issue -, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/oncolo/oyad262
Keywords
-
Categories
Ask authors/readers for more resources
This review examines the molecular characteristics and clinical trials of anti-EGFR antibodies in the treatment of advanced colorectal cancer. It discusses the clinical implications of biomarkers for treatment selection, different dosing strategies, and side effect management. The review also explores future directions, particularly the combination of these antibodies with MAPK-targeted therapies and immunotherapy.
Colorectal cancer is the third most common cancer worldwide, and incidence is rising in younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have been incorporated into standard-of-care practice for patients with advanced disease. Herein, we review the molecular characteristics of these agents and the trials that lead to their approvals. Further, we discuss clinical implications of data regarding biomarkers that dictate treatment selection, different dosing strategies, and side effect management. Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available